Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma

Yıl: 2021 Cilt: 28 Sayı: 12 Sayfa Aralığı: 2160 - 2167 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2021.03.220

Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma

Öz:
Aim: The excision repair cross-complementation group 1 (ERCC-1) protein is a potential prognostic biomarker of the efficacy of platinum-based chemotherapy in non–small-cell lung cancer (NSCLC). The purpose of this study was to evaluate the clinicopathology and prognostic significance of ERCC-1 expression, ERCC-1 (19q13) amplification in NSCLC patients; and the relationship between platinum-based chemotherapy. Materials and Methods: We used the ERCC-1 antibody to measure the level of expression of ERCC-1 protein by immunohistochemical analysis from 351 patients and ERCC-1 gene copy number was evaluated by fluorescence in situ hybridization (FISH) in tumors from 81 patients. Results: ERCC-1 expression in tumor cells was positive in 312 patients (88.9%). The ERCC-1 amplification in tumor cells was positive in 58 patients (71.6%) out of 81. The ERCC-1 amplification was also more frequent in early-stage tumors than late-stage tumors (p = 0.025). In the patients with positive ERCC-1 expression, longer overall survival was associated with early stage NSCLC (p = 0.001). Patients having adenocarcinoma with negative ERCC-1 expression demonstrated longer overall survival than patients with squamous cell carcinoma (p = 0.037). Conclusion: Our study demonstrated that increased ERCC-1 amplification is not associated with ERCC-1 protein expression. High ERCC-1 expression in patients with early-stage NSCLC is a good prognostic factor, although it is a negative predictor, indicating treatment resistance, in patients with advanced-stage NSCLC receiving platinum-based chemotherapy. We suggest that patients having adenocarcinoma with negative ERCC-1 expression benefit more with platinum-based chemotherapies.
Anahtar Kelime:

Konular:
Fen > Tıp > Anatomi ve Morfoloji
Fen > Tıp > Androloji
Fen > Tıp > Biyofizik
Fen > Tıp > Biyokimya ve Moleküler Biyoloji
Fen > Tıp > Dermatoloji
Fen > Tıp > Acil Tıp
Fen > Tıp > Hematoloji
Fen > Tıp > Enfeksiyon Hastalıkları
Fen > Tıp > Tıbbi İnformatik
Fen > Tıp > Tıbbi Laboratuar Teknolojisi
Fen > Tıp > Nörolojik Bilimler
Fen > Tıp > Onkoloji
Fen > Tıp > Göz Hastalıkları
Fen > Tıp > Kulak, Burun, Boğaz
Fen > Tıp > Patoloji
Fen > Tıp > Romatoloji
Fen > Tıp > Spor Bilimleri
Fen > Tıp > Adli Tıp
Fen > Tıp > Tıbbi Araştırmalar Deneysel
Fen > Tıp > Periferik Damar Hastalıkları
Fen > Tıp > Üroloji ve Nefroloji
Fen > Tıp > Kadın Hastalıkları ve Doğum
Fen > Tıp > Geriatri ve Gerontoloji
Fen > Tıp > Temel Sağlık Hizmetleri
Fen > Tıp > Alerji
Fen > Tıp > Odyoloji ve Konuşma-Dil Patolojisi
Fen > Tıp > Biyoteknoloji ve Uygulamalı Mikrobiyoloji
Fen > Tıp > Hücre Biyolojisi
Fen > Tıp > Klinik Nöroloji
Fen > Tıp > Yoğun Bakım, Tıp
Fen > Tıp > Tıbbi Etik
Fen > Tıp > Ortopedi
Fen > Tıp > Pediatri
Fen > Tıp > Solunum Sistemi
Fen > Tıp > Cerrahi
Fen > Temel Bilimler > Biyoloji
Fen > Tıp > Halk ve Çevre Sağlığı
Fen > Tıp > Sağlık Bilimleri ve Hizmetleri
Fen > Eczacılık > Toksikoloji
Fen > Diş Hekimliği > Diş Hekimliği
Fen > Diş Hekimliği
Fen > Tıp > Anestezi
Fen > Tıp > İmmünoloji
Fen > Tıp > Mikrobiyoloji
Fen > Tıp > Fizyoloji
Fen > Tıp > Psikiyatri
Fen > Tıp > Rehabilitasyon
Fen > Tıp > Transplantasyon
Fen > Tıp > Tropik Tıp
Fen > Tıp > Tamamlayıcı ve Entegre Tıp
Fen > Tıp > Genel ve Dahili Tıp
Fen > Tıp > Gastroenteroloji ve Hepatoloji
Fen > Tıp > Endokrinoloji ve Metabolizma
Fen > Tıp > Kalp ve Kalp Damar Sistemi
Fen > Eczacılık > Farmakoloji ve Eczacılık
Fen > Tıp > Radyoloji, Nükleer Tıp, Tıbbi Görüntüleme
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute 2019.
  • 2. Jeong YH, Lee C kun, Jo K, et al. Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer. Nucl Med Mol Imaging 2015;49:108-14.
  • 3. Taillade L, Penault-Llorca F, Boulet T, et al. Immunohistochemichal expression of biomarkers: A comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 2007;18:1043-50.
  • 4. Bilen N, Tekin SB, Topdagi O. ERCC1 expression in non-small cell lung cancer and esophageal cancer. Eurasian J Med 2014;46:84-8.
  • 5. Vanhecke E, Valent A, Tang X, et al. 19q13-ERCC1 gene copy number increase in non-small-cell lung cancer. Clin Lung Cancer 2013;14:549-57.
  • 6. Andrews TD, Baird JW, Wallace WAH, et al. Routinely obtained diagnostic material as a source of rna for personalized medicine in lung cancer patients. J Thorac Oncol 2011;6:884-8.
  • 7. Bogush TA, Dudko EA, Grishanina AN, et al. Flow cytometric analysis of the ERCC1, marker of DNA damage repair, in the tumor specimens embedded into paraffin blocks. Dokl Biochem Biophys 2017;472:9- 11.
  • 8. Shen H, Zhu Y, Wu Y jie, et al. Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genet Cytogenet 2008;181:100-7.
  • 9. Li J, Zhang W, Guo N, et al. Expression of molecular markers in primary sites and metastatic lymph nodes of lung cancer patients. Med Sci Monit 2017;23:513- 20.
  • 10. Liao WY, Ho CC, Tsai TH, et al. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Lung Cancer 2018;118:90-6.
  • 11. Yildiz OO, Celik IA. Methastatic N2 in T1 Non-small cell lug cancer: Should we go back to invasive staging? Ann Med Res 2020;27:1616-20.
  • 12. Hubner RA, Riley RD, Billingham LJ, et al. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: A meta-analysis of published studies and recommendations. PLoS One 2011;6:1-10.
  • 13. Aiello MM, Solinas C, Santoni M, et al. Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced NonSmall Cell Lung Cancer. Front Oncol 2020;10:1167.
  • 14. Villalobos M, Czapiewski P, Reinmuth N, et al. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV nonsquamous non-small cell lung cancer. Med Oncol 2018;35:106.
  • 15. Jiang J, Liang X, Zhou X, et al. ERCC1 expression as a prognostic and predictive factor in patients with nonsmall cell lung cancer: A meta-analysis. Mol Biol Rep 2012;39:6933-42.
  • 16. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-25.
  • 17. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with nonsmall cell lung cancer. Chest. 2005;127:978-83.
  • 18. Honma HN, Perroud MW, Morcillo AM, et al. Response to cytotoxic chemotherapy and overall survival in non-small cell lung cancer patients with positive or negative ERCC1 expression. J Bras Pneumol 2018;44:245-6.
  • 19. Breen D, Barlési F. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg 2008;33:805-11.
  • 20. Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced NonSmall-Cell Lung Cancer: ERCC1 Trial (ET). J Clin Oncol 2017;35:402-11.
  • 21. Aiello MM, Solinas C, Santoni M, et al. Aiello MM, Solinas C, Santoni M, et al. Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced NonSmall Cell Lung Cancer. Front Oncol 2020;10:1167. Published 2020 Sep 2.
APA BİR F, DOĞU G, KARAKAYA Y, BAŞER S, GORMEZ A (2021). Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma. Annals of Medical Research, 28(12), 2160 - 2167. 10.5455/annalsmedres.2021.03.220
Chicago BİR Ferda,DOĞU Gamze GÖKÖZ,KARAKAYA Yeliz ARMAN,BAŞER Sevin,GORMEZ Aysegul Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma. Annals of Medical Research 28, no.12 (2021): 2160 - 2167. 10.5455/annalsmedres.2021.03.220
MLA BİR Ferda,DOĞU Gamze GÖKÖZ,KARAKAYA Yeliz ARMAN,BAŞER Sevin,GORMEZ Aysegul Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma. Annals of Medical Research, vol.28, no.12, 2021, ss.2160 - 2167. 10.5455/annalsmedres.2021.03.220
AMA BİR F,DOĞU G,KARAKAYA Y,BAŞER S,GORMEZ A Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma. Annals of Medical Research. 2021; 28(12): 2160 - 2167. 10.5455/annalsmedres.2021.03.220
Vancouver BİR F,DOĞU G,KARAKAYA Y,BAŞER S,GORMEZ A Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma. Annals of Medical Research. 2021; 28(12): 2160 - 2167. 10.5455/annalsmedres.2021.03.220
IEEE BİR F,DOĞU G,KARAKAYA Y,BAŞER S,GORMEZ A "Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma." Annals of Medical Research, 28, ss.2160 - 2167, 2021. 10.5455/annalsmedres.2021.03.220